Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314716 | 0.77 | MEN1 (0.36) | LMNAALDH1A1KMT2AMEN1ABCC4 | |
| SCHEMBL9835125 | 0.64 | HSD17B10 (0.43) | LMNAALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL11712299 | 0.63 | LMNA (0.40) | LMNAALDH1A1KMT2AMEN1ABCC4 | |
| SCHEMBL11407347 | 0.63 | MEN1 (0.68) | LMNAALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL9836136 | 0.63 | DAO (0.42) | LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL16166425 | 0.62 | ALDH1A1 (0.43) | LMNAALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL16469269 | 0.62 | LMNA (0.49) | LMNAKMT2AMEN1ABCC4PKM | |
| SCHEMBL7288734 | 0.62 | KMT2A (0.42) | LMNAKMT2AMEN1 | |
| SCHEMBL18966034 | 0.61 | PIK3CB (0.36) | ALDH1A1KMT2AMEN1IKBKBCHUK | |
| SCHEMBL12665406 | 0.60 | LMNA (0.47) | LMNAKMT2AMEN1ABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737159-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | ABBVIE INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196200-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, FDPS, PGLS | LMNA 3464/4885ALDH1A1 2936/4885MAPK1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.